THOUSAND OAKS, Calif.,
Feb. 3, 2017 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) today announced the appointment of Charles M. Holley Jr. to the Amgen Board of
Directors. Mr. Holley will serve as a member of the Audit Committee
and the Corporate Responsibility and Compliance Committee of the
Board. Following the appointment of Mr. Holley, the Board will
comprise 15 directors, 14 of whom are independent.
"Charles Holley brings deep
financial and organizational experience from one of the world's
largest and most successful companies," said Robert A. Bradway, chairman and chief executive
officer of Amgen. "We welcome Charles to Amgen's Board as we
work to shape an exciting future."
Mr. Holley, 60, is the former Executive Vice President and Chief
Financial Officer for Wal-Mart Stores, Inc. ("Walmart") where he
served from 2010 to 2015 and as Executive Vice President between
Jan. 1, 2016, and Jan. 31, 2016. Prior to this, Mr. Holley served
as Executive Vice President, Finance and Treasurer of Walmart from
2007 to 2010. From 2005 through 2006, he served as Senior
Vice President. Prior to that, Mr. Holley was Senior Vice President
and Controller from 2003 to 2005. Mr. Holley served in various
roles in Wal-Mart International from 1994 through 2002. Prior to
this, Mr. Holley served in various roles at Tandy Corporation. He
spent more than ten years with Ernst & Young LLP. Mr. Holley is
an Independent Senior Advisor, U.S. CFO Program, Deloitte LLP, a
privately-held provider of audit, consulting, tax, and advisory
services.
Mr. Holley serves on the Dean's Advisory Board for the McCombs
School of Business at the University of Texas
at Austin and the University of
Texas Presidents' Development Board.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer
since 1980, Amgen has grown to be one of the world's leading
independent biotechnology companies, has reached millions of
patients around the world and is developing a pipeline of medicines
with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008
(media)
Trish Hawkins, 805-447-5631
(media)
Arvind Sood, 805-447-1060
(investors)
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-announces-appointment-of-charles-m-holley-jr-to-board-of-directors-300402112.html
SOURCE Amgen